Skip to content

A clinical study to evaluate the efficacy and safety of MegaCarti® as a treatment for cartilage regeneration in patients with knee joint cartilage injury : Multicenter, microfracture control, randomization, superiority clinical trial

A clinical study to evaluate the efficacy and safety of MegaCarti® as a treatment for cartilage regeneration in patients with knee joint cartilage injury : Multicenter, microfracture control, randomization, superiority clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CRIS
Registry ID
KCT0008226
Enrollment
64
Registered
2023-02-23
Start date
2023-05-02
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Subject who meet the inclusion criteria are assigned according to the IWRS. On the day of surgery, subjects undergo knee cartilage surgery under anesthesia. According to the assigned

Sponsors

Yeongnam University Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All subjects can participate in the clinical trial only when all of the following criteria are met. ? 51 years to 65 years ? Subject or legal representatives who voluntarily decide to participate in the clinical trial and give written consent after hearing a detailed explanation of this clinical trial and fully understanding it ? Defect: International Cartilage Repair Society(ICRS) Grade III or IV single defect chondral lesion on knee cartilage ? Subject whose primary lesion site can be designated as one section of the knee joint, and the area can be determined as the main cause of clinical symptoms ? Knee cartilage defect size : below 10cm2 ? Subject who need concurrent Misalignment correction osteotomy(Subject who perform high tibial osteotomy due to varus deformity above -5 degrees in Hip-knee-ankle angle)

Exclusion criteria

Exclusion criteria: If any of the following items apply, the subject is excluded from the clinical trial. ? Subject who have autoimmune disease (Ex. Rheumatoid arthritis) ? When screening, Subject who have had trauma or cartilage damage or have undergone ligament surgery in the same knee as the surgical site within the past 1 year ? When screening, Subject who underwent surgery related to cartilage defect treatment, such as microfracture, autologous chondrocyte therapy in the same knee joint as the surgical site within the past year (Possible for arthroscopy for diagnostic purposes) ? When screening, Subject who received intra-articular hyaluronic acid or steroid injection in the same knee as the surgical site within 2 months ? When screening, Subject who took oral steroids within 1 month ? Subject taking immunosuppressive drugs or immune disorder ? Subject with a history of cancer within the past 5 years ? BMI index : 35kg/m2 or more ? Subject with have gout or gout history in the same knee as the surgical site ? Subject who are pregnant, lactating or unable to use contraception ? Drug and alcohol addiction / dependence or mental disorder ? Subject with risk factor for bleeding (subject taking antithrombotic drugs other than aspirin) ? Subject who have localized knee infection in the same knee as the surgical site ? Subject who are judged by medical investigator to be considered unsuitable for this clinical trial

Design outcomes

Primary

MeasureTime frame
Pain score of KOOS(Knee injury and Osteoarthritis Outcome Score)

Secondary

MeasureTime frame
KOOS (Knee injury and Osteoarthritis Outcome Score);WOMAC (Western Ontario & McMaster Universities);VAS (Visual Analogue Scale);Evaluation of cartilage regeneration

Countries

Korea, Republic of

Contacts

Public ContactGi Beom Kim

Yeongnam University Medical Center

yumcknee@naver.com+82-53-620-3640

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026